Heparin induced thrombocytopenia: diagnosis and management update

被引:195
作者
Ahmed, I.
Majeed, A.
Powell, R.
机构
[1] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England
[2] Worcester Royal Hosp, Worcester, England
[3] Leicester Gen Hosp, Leicester LE5 4PW, Leics, England
关键词
D O I
10.1136/pgmj.2007.059188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin. Despite thrombocytopenia, bleeding is rare; rather, HIT is strongly associated with thromboembolic complications involving both the arterial and venous systems. A number of laboratory tests are available to confirm the diagnosis; however, when HIT is clinically suspected, treatment should not be withheld pending the result. Fortunately, therapeutic strategies have been refined, and new and effective therapeutic agents are available. Treatment options are focused on inhibiting thrombin formation or direct thrombin inhibition. Warfarin should not be used until the platelet count has recovered.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 53 条
[41]   Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia [J].
Opatrny, L ;
Warner, MN .
AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (03) :240-244
[42]   Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia [J].
Pinto, DS ;
Sperling, RT ;
Tu, TM ;
Cohen, DJ ;
Carrozza, JP .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (01) :65-68
[43]   The pathophysiology of immune-mediated heparin-induced thrombocytopenia [J].
Reilly, RF .
SEMINARS IN DIALYSIS, 2003, 16 (01) :54-60
[44]   Heparin-induced thrombocytopenia - Myths and misconceptions (that will cause trouble for you and your patient) [J].
Rice, L .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (18) :1961-1964
[45]   Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome [J].
Strauss, R ;
Wehler, M ;
Mehler, K ;
Kreutzer, D ;
Koebnick, C ;
Hahn, EG .
CRITICAL CARE MEDICINE, 2002, 30 (08) :1765-1771
[46]   The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction [J].
Swan, SK ;
Hursting, MJ .
PHARMACOTHERAPY, 2000, 20 (03) :318-329
[47]  
Vanholder R, 1997, THROMB HAEMOSTASIS, V77, P650
[48]   Impact of the patient population on the risk for heparin-induced thrombocytopenia [J].
Warkentin, TE ;
Sheppard, JAI ;
Horsewood, P ;
Simpson, PJ ;
Moore, JC ;
Kelton, JG .
BLOOD, 2000, 96 (05) :1703-1708
[49]   Delayed-onset heparin-induced thrombocytopenia and thrombosis [J].
Warkentin, TE ;
Kelton, JG .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :502-506
[50]   HEPARIN-INDUCED THROMBOCYTOPENIA IN PATIENTS TREATED WITH LOW-MOLECULAR-WEIGHT HEPARIN OR UNFRACTIONATED HEPARIN [J].
WARKENTIN, TE ;
LEVINE, MN ;
HIRSH, J ;
HORSEWOOD, P ;
ROBERTS, RS ;
GENT, M ;
KELTON, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1330-1335